Up next

Autoplay

PI3K and PARP Inhibitors in HR+ Metastatic Breast Cancer

15 Views • 07/03/23
Share
Embed
administrator
administrator
Subscribers
0

Joyce A. O’Shaughnessy, MD, and Andrew D. Seidman, MD, evaluate treatment options outside of CDK4/6 inhibition, such as PI3-kinase or poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors, for patients with hormone-receptor positive metastatic breast cancer.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay